Acute Kidney Injury Due to Sepsis
15
4
5
6
Key Insights
Highlights
Success Rate
86% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
6.7%
1 terminated out of 15 trials
85.7%
-0.8% vs benchmark
7%
1 trials in Phase 3/4
33%
2 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (15)
Phase 2b Study to Investigate the Safety and Efficacy of TIN816 in Sepsis-associated Acute Kidney Injury (CLEAR-AKI)
Use of NGAL for Fluid Dosing and CRRT Initiation in Pediatric and Neonatal AKI
QUELIMMUNE (SCD-PED) PediAtric SurVeillance REgistry
Hemodynamic Resuscitation Guided by Non-Invasive Mean Systemic Filling Pressure to Prevent Acute Kidney Injury in Septic Shock
Comparison of Plasma Neutrophil Gelatinase-Associated Lipocalin (pNGAL) Level in De-resuscitation With Furosemide Group and Control Group
Pharmacokinetics and Safety of TIN816 in Patients With Sepsis-associated Acute Kidney Injury
Endogenous Lithium Clearance in Acute Kidney Injury
Hemodynamic Stability in Septic Shock Patients Undergoing Continuous Renal Replacement Therapy With oXiris Membrane
miRNA in Septic Acute Kidney Injury
(Revival) Study to Investigate the Efficacy and Safety of Alkaline Phosphatase in Patients With Sepsis-Associated AKI
Renin Angiotensin Aldosterone System In Septic Kids
N/LP Ratio as Predictor of Mortality in Septic AKI Patients
Presepsin:Gelsolin Ratio in Sepsis-related Organ Dysfunction
Urinary Actin, as a Potential Marker of Sepsis-related Acute Kidney Injury
Plasma Endostatin Predicts Outcome of Septic AKI